MetaCap

Clearmind Medicine (CMND) vs GeoVax Labs (GOVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Clearmind Medicine is the larger company by market cap ($1.3 million vs $985,459), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CMND-60.15%GOVX+525.43%
+682%+292%-97%
Oct 7, 20261 yearNov 20, 2026
CMND-60.03%GOVX+544.13%
+574%+242%-90%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CMND versus GOVX key metrics
MetricCMNDGOVX
Share price$2.63$1.81
Market cap$1.33M$985.46K
1-day change-17.68%-5.24%
EPS (TTM)$-461.20$-15.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.49M
Revenue growth (YoY)—-37.06%
Net income (latest FY)$-3.86M$-21.46M
Operating margin—-869.34%
Net margin—-862.34%
52-week high$649.60$270.60
52-week low$2.63$1.51
Distance from 52-week high-99.60%-99.33%
Analyst consensus—none
Avg. price target upside—+452.49%
Average volume55.57K213.41K
Shares outstanding507.40K544.45K
Employees—19
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Clearmind Medicine

CMND stock →

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.

Health Care · Biotechnology: Pharmaceutical Preparations

About GeoVax Labs

GOVX stock →

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

CMND vs GOVX FAQ

Which is bigger, Clearmind Medicine or GeoVax Labs?

Clearmind Medicine (CMND) is larger, with a market capitalization of $1.33M compared with $985.46K for GeoVax Labs (GOVX).

Are Clearmind Medicine and GeoVax Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons